2017 Press Releases


Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
03/30/17Bellicum Pharmaceuticals Announces Closing of Public Offering
HOUSTON, March 30, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) today announced the closing, on March 29, 2017, of its previously announced underwritten public offering of 5,750,000 shares of its common stock, including 750,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a public offering price of $12.00 per share. The aggregate offering size was approximately $69.0 million, before deducting the underwriting... 
Printer Friendly Version
03/23/17Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock
HOUSTON, March 23, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $12.00 per share. The aggregate offering size, before deducting the underwriting discounts and commissions and other offering expenses, is expected to be approximately $60.0 million. The offering is expected to close on or about March 29, 2017, subject to customary closing cond... 
Printer Friendly Version
03/22/17Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock
HOUSTON, March 22, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. Bellicum expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 750,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions. All shares of common stock to be sold in the offering will be offered by Bell... 
Printer Friendly Version
03/13/17Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
On track to complete enrollment in E.U. registration trials for BPX-501 and rimiducid this year Reported updated clinical data with BPX-501 demonstrating rapid immune recovery and low rates of GvHD in children with blood cancers and orphan inherited blood disorders Initiated clinical trials of controllable CAR T and TCR product candidates  Management to host conference call and webcast today at 5 p.m. Eastern HOUSTON, March 13, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nas... 
Printer Friendly Version
03/08/17Bellicum Pharmaceuticals to Present at the Barclays Global Healthcare Conference
HOUSTON, March 08, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a corporate overview at the Barclays Global Healthcare Conference on Wednesday, March 15 at 4:20 p.m. EDT in Miami, FL. A live webcast of the presentation may be accessed from the News & Events section of the... 
Printer Friendly Version
03/06/17Bellicum to Report Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call and Webcast on March 13, 2017
HOUSTON, March 06, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company will host a conference call and live webcast on Monday, March 13, 2017 at 5:00 p.m. Eastern to report its fourth quarter and full year 2016 financial results and provide a corporate update. To access the call, participants should dial 877-407-3103 (U.S. ... 
Printer Friendly Version
02/22/17Bellicum Presents Updated Clinical Results at 2017 BMT Tandem Meetings on BPX-501 in Orphan Inherited Blood Disorders and Hematologic Cancers
Study demonstrates consistent, durable outcomes at six and 12 months with very low incidence of GvHD HOUSTON, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the presentation of updated clinical results from its multicenter BP-004 clinical trial of BPX-501 and rimiducid at the 2017 BMT Tandem Meetings. Results on 73 patients with... 
Printer Friendly Version
02/21/17Bellicum Announces Initiation of Patient Dosing with Controllable CAR T-Cell Product Candidate
BPX-601 being studied in pancreatic cancers expressing PSCA HOUSTON, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced it has dosed the first patient with BPX-601, the first CAR T-cell product candidate to enter clinical studies that is designed to enable control over the expansion and stimulation of the cells. BPX-601 targets soli... 
Printer Friendly Version
01/31/17Bellicum Announces Appointment of Rick Fair as Chief Executive Officer in Preparation for Commercialization of BPX-501 and Next Phase of Growth
HOUSTON, Jan. 31, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the appointment of Rick Fair as President and Chief Executive Officer, and as a member of the Board of Directors, effective immediately. Mr. Fair joins Bellicum from Genentech/Roche, where he was Senior Vice President, Head of Onco... 
Printer Friendly Version